Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy (Intra Op)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04182997 |
Recruitment Status :
Recruiting
First Posted : December 2, 2019
Last Update Posted : December 2, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lumbar Disc Herniation | Drug: Dexamethasone Drug: saline 0.9% | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Patients will be randomly assigned to either the treatment group or the placebo group. At the end of surgery patients in the treatment group will have the surgical site lavaged with dexamethasone while patients in the placebo group will have the surgical site lavaged by sterile saline. |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | the patient and any treating physicians will be blinded to which arm the patient was assigned. This will be accomplished by the research coordinator determining the randomization status and passing this information along to a surgical nurse. The nurse will the procure either the placebo or treatment drug and give it to the treating physician in an non-descript container so that the appearance will not give away the type of liquid being used. |
Primary Purpose: | Treatment |
Official Title: | Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy for Herniated Lumbar Discs Is There a Role? - A Randomized Control Trial |
Actual Study Start Date : | November 21, 2019 |
Estimated Primary Completion Date : | October 2020 |
Estimated Study Completion Date : | October 2021 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo Group
Patients in this group will be given the placebo (sterile saline).
|
Drug: saline 0.9%
Patients included in the placebo group will have their surgical site lavaged with sterile saline at the end of their surgery.
Other Name: sterile saline |
Active Comparator: Dexamethasone Group
Patients in this group will be given the study drug (dexamethasone).
|
Drug: Dexamethasone
Patients included in the treatment group will have their surgical site lavaged with dexamethasone at the end of their surgery. |
- Post Operative Pain Scores [ Time Frame: Until final follow up (up to 8 weeks) ]Comparing post operative pain scores between treatment and placebo group. Using VAS pain score with scale 0 to 10 with 0 being no pain and 10 being the worst pain of your life.
- Length of stay [ Time Frame: Until final follow up (up to 8 weeks) ]Determining how long patient is in hospital
- Post Operative Opioid Usage [ Time Frame: Until final follow up (up to 8 weeks) ]comparing opioid usage post operatively
- Post Operative Complications [ Time Frame: Until final follow up (up to 8 weeks) ]comparing rate of post-op infections

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Presenting to the University of Missouri hospital system - including the University of Missouri Hospital and Missouri Orthopaedic Institute - with a clinical assessment indicative of a lumbar disc herniation
- Failed conservative treatment - rest, anti-inflammatory medications, physical therapy
- Radiculopathy present - positive tension signs or sensory/motor neurologic deficits present
- Recent MRI confirming single-level lumbar disc herniation corresponding to clinical evaluation
Exclusion Criteria:
- Concomitant spinal stenosis, segmental instability, or spondylolisthesis
- Previous surgery at the affected level or recurrent herniation
- Underlying disease that may affect response to steroids - immunocompromise, use of chronic steroids or immunosuppression
- Pregnancy - qualitative beta hCG testing will be performed prior to enrollment
- Diagnosis of or symptoms concerning for cauda equina syndrome

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04182997
Contact: Stacee Clawson, BSN, RN | (573) 884-9017 | clawsons@health.missouri.edu |
United States, Missouri | |
University of Missouri Health System | Recruiting |
Columbia, Missouri, United States, 65212 | |
Contact: Susan Kady, BSN, RN 573-884-1925 kadysj@missouri.edu | |
Principal Investigator: Don Moore, MD | |
Sub-Investigator: Theodore Choma, MD | |
Sub-Investigator: Muhammad Mirza, MD |
Publications of Results:
Responsible Party: | Don Moore, Assistant Professor, Orthopedic Surgery, University of Missouri-Columbia |
ClinicalTrials.gov Identifier: | NCT04182997 History of Changes |
Other Study ID Numbers: |
2014147 |
First Posted: | December 2, 2019 Key Record Dates |
Last Update Posted: | December 2, 2019 |
Last Verified: | November 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Hernia Pathological Conditions, Anatomical Dexamethasone Dexamethasone acetate BB 1101 Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |